1. Tarsus plans to join two upcoming investor conferences. 2. Conferences include Wells Fargo and H.C. Wainwright events in September. 3. Tarsus aims to showcase advancements in eye care and disease prevention.
Participation in high-profile conferences often boosts investor interest and awareness. Past patterns show a positive trend in stocks around conference announcements.
The announcement of participating in investor conferences generally creates positive sentiment and can attract new investors. This is especially critical for Tarsus as it seeks visibility and support for its ongoing projects.
Upcoming conferences are imminent, likely influencing stock performance in the near term. Historical data suggest that stocks often react shortly after such events.
IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences:
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
